Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Tokio Marine Asset Management Co. Ltd.

Tokio Marine Asset Management Co. Ltd. grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 2.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 15,728 shares of the medical research company’s stock after purchasing an additional 316 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Amgen were worth $4,099,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Inlet Private Wealth LLC grew its holdings in shares of Amgen by 1.7% during the fourth quarter. Inlet Private Wealth LLC now owns 23,832 shares of the medical research company’s stock valued at $6,212,000 after purchasing an additional 401 shares during the last quarter. Independence Bank of Kentucky boosted its position in Amgen by 109.9% during the 4th quarter. Independence Bank of Kentucky now owns 2,960 shares of the medical research company’s stock valued at $771,000 after purchasing an additional 1,550 shares during the period. Evermay Wealth Management LLC boosted its position in Amgen by 1.5% during the 4th quarter. Evermay Wealth Management LLC now owns 2,650 shares of the medical research company’s stock valued at $691,000 after purchasing an additional 38 shares during the period. Blossom Wealth Management increased its position in Amgen by 3.5% in the fourth quarter. Blossom Wealth Management now owns 1,090 shares of the medical research company’s stock worth $284,000 after buying an additional 37 shares during the period. Finally, KG&L Capital Management LLC lifted its stake in Amgen by 37.7% in the fourth quarter. KG&L Capital Management LLC now owns 3,881 shares of the medical research company’s stock valued at $1,011,000 after buying an additional 1,063 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on AMGN. Jefferies Financial Group restated a “buy” rating and issued a $380.00 target price on shares of Amgen in a research report on Tuesday, November 12th. Redburn Partners lowered their target price on Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. UBS Group cut their target price on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research note on Thursday, October 31st. Truist Financial decreased their price target on Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a research note on Wednesday, January 8th. Finally, StockNews.com cut shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $314.00.

Amgen Trading Up 0.5 %

Amgen stock opened at $285.42 on Monday. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The firm has a market capitalization of $153.42 billion, a price-to-earnings ratio of 36.55, a P/E/G ratio of 2.85 and a beta of 0.56. The company has a 50 day moving average price of $271.06 and a 200 day moving average price of $304.33.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be issued a dividend of $2.38 per share. This is an increase from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.34%. Amgen’s payout ratio is currently 121.90%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.